Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198329 | 0.85 | RAB9A (0.38) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| Ammonia Solution, Strong SCHEMBL2287120 | 0.84 | RAB9A (0.37) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL2199232 | 0.83 | MAPT (0.48) | NPC1RAB9ALMNAMAPTALDH1A1 | |
| SCHEMBL4890520 | 0.80 | FABP4 (0.44) | LMNAMAPT | |
| SCHEMBL7990801 | 0.79 | CYP2E1 (0.53) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| Hydrochloric Acid SCHEMBL28812335 | 0.78 | PDE10A (0.48) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL2910946 | 0.77 | CYP2E1 (0.67) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL5924494 | 0.76 | PDE10A (0.47) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL651699 | 0.76 | CYP2E1 (0.50) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 | |
| SCHEMBL12985062 | 0.76 | CYP2E1 (0.42) | PDE10AHPGDSCYP2E1CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214698-B2 | Beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-08 | — | — | US | disclosed |
| US-20060173061-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-03 | — | — | US | disclosed |
| US-20040127733-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173061-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | ADRB1, ADRB2, ADRA1A | PDE10A 101/4885HPGDS 1243/4885CYP2E1 511/4885 |
| US-20040127733-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | ADRB1, ADRA1A, ADRA1D | PDE10A 86/4885HPGDS 1194/4885CYP2E1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.